PE20231320A1 - Biofactores para el tratamiento y la profilaxis de la demencia - Google Patents

Biofactores para el tratamiento y la profilaxis de la demencia

Info

Publication number
PE20231320A1
PE20231320A1 PE2023001360A PE2023001360A PE20231320A1 PE 20231320 A1 PE20231320 A1 PE 20231320A1 PE 2023001360 A PE2023001360 A PE 2023001360A PE 2023001360 A PE2023001360 A PE 2023001360A PE 20231320 A1 PE20231320 A1 PE 20231320A1
Authority
PE
Peru
Prior art keywords
biofactors
dementia
prophylaxis
treatment
vitamin
Prior art date
Application number
PE2023001360A
Other languages
English (en)
Inventor
Fritz Worwag
Marcus Worwag
Original Assignee
Worwag Pharma Gmbh And Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Worwag Pharma Gmbh And Co Kg filed Critical Worwag Pharma Gmbh And Co Kg
Publication of PE20231320A1 publication Critical patent/PE20231320A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere una combinacion de biofactores que comprenden orotato de magnesio y acido folico o folatos, o tautomeros y sales de los mismos. Tambien esta referida a otras combinaciones que comprenden ademas orotato de zinc, vitamina D, vitamina B y benfotiamina. Dichas combinaciones estan comprendidas en un suplemento medicinal o nutricional, la cual es util en el tratamiento y la profilaxis de la demencia y la disfuncion mitocondrial.
PE2023001360A 2020-10-07 2021-10-07 Biofactores para el tratamiento y la profilaxis de la demencia PE20231320A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20200644.1A EP3981407A1 (de) 2020-10-07 2020-10-07 Biofaktoren zur behandlung und prophylaxe von demenz
PCT/EP2021/077684 WO2022074114A1 (de) 2020-10-07 2021-10-07 Biofaktoren zur behandlung und prophylaxe von demenz

Publications (1)

Publication Number Publication Date
PE20231320A1 true PE20231320A1 (es) 2023-08-24

Family

ID=72801432

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001360A PE20231320A1 (es) 2020-10-07 2021-10-07 Biofactores para el tratamiento y la profilaxis de la demencia

Country Status (14)

Country Link
EP (2) EP3981407A1 (es)
JP (1) JP2023545721A (es)
KR (1) KR20230121996A (es)
CN (1) CN116322695A (es)
AR (1) AR123714A1 (es)
BR (1) BR112023006333A2 (es)
CA (1) CA3198067A1 (es)
CL (1) CL2023001016A1 (es)
CO (1) CO2023004351A2 (es)
MX (1) MX2023004107A (es)
PE (1) PE20231320A1 (es)
TW (1) TW202237121A (es)
WO (1) WO2022074114A1 (es)
ZA (1) ZA202304043B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420342B1 (en) * 2000-05-08 2002-07-16 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof
DE102009025549A1 (de) * 2009-06-15 2010-12-16 Werth Akupunktur Center Zusammensetzung für den Transport von Orotsäure über die Bluthirnschranke
US20150132273A1 (en) 2013-11-09 2015-05-14 Rhett Sean Daniels Nutritional Compositions and Methods for Treating Cognitive Impairment
WO2017059895A1 (en) 2015-10-07 2017-04-13 Parthenogen Sagl Dietary supplementation to achieve oxy-redox homeostasis and genomic stability
EP3443965A4 (en) 2016-04-15 2020-02-19 Hirokawa, Yoshihiro MEANS FOR HEALING THE COGNITIVE FUNCTION
DE202017006840U1 (de) * 2017-03-03 2018-07-26 Glycana UG (haftungsbeschränkt) Nahrungsergänzungsmittel umfassend einen Galaktose-haltigen Multivitamin-Mineralstoffkomplex

Also Published As

Publication number Publication date
WO2022074114A1 (de) 2022-04-14
EP3981407A1 (de) 2022-04-13
EP4225318A1 (de) 2023-08-16
CO2023004351A2 (es) 2023-07-10
AR123714A1 (es) 2023-01-04
JP2023545721A (ja) 2023-10-31
CN116322695A (zh) 2023-06-23
CA3198067A1 (en) 2022-04-14
MX2023004107A (es) 2023-08-07
BR112023006333A2 (pt) 2023-05-09
TW202237121A (zh) 2022-10-01
CL2023001016A1 (es) 2023-11-17
ZA202304043B (en) 2024-04-24
KR20230121996A (ko) 2023-08-22

Similar Documents

Publication Publication Date Title
CO2019001634A2 (es) Compuestos de pirrolizina sustituida y usos de los mismos.
AR099307A1 (es) Sales de triazolo piridina para el tratamiento de trastornos inflamatorios
CO6400175A2 (es) Complementos nutricionales para individuos de 50 años de edad o más para mejorar la vitalidad, inmunidad, y salud ocular y ósea
CR9146A (es) Sal potasica de un inhibidor de la integrasa de vih
CL2017001112A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
WO2015073055A8 (en) Micronutrient formulations for concussive brain injuries
GT201200138A (es) Derivados de sulfonamida heterocíclicos útiles como inhibidores de mek
CR20200464A (es) Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
CL2019003402A1 (es) Composiciones sólidas para administración oral.
CO2017000011A2 (es) Derivados de quinolizinona como inhibidores de pi3k
PA8566301A1 (es) Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades
PA8566501A1 (es) Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades
CO6612202A2 (es) Inhibidores heterparílicos bicíclicos de pde4
PE20231320A1 (es) Biofactores para el tratamiento y la profilaxis de la demencia
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
AR094979A1 (es) Concentrado alimenticio salado fortificado
CO2019003255A2 (es) Composición que comprende una combinación de un anáologo de trh con ácido arúndico y una sal farmacéuticamente aceptable de ácido arúndico
PE20170902A1 (es) Composicion dietetica con actividad antidislipidemica
AR110542A1 (es) Composiciones nutricionales que contienen inositol y usos de las mismas
CL2009001956A1 (es) Composicion nutracéutica que comprende extracto de shilajit (250-500 mg), acido folico (200-500 ug), vitamina b6(20-40 ug), vitamina b12 (4-8 ug) y excipientes aceptables; metodo de fabricacion; y su uso para prevenir o tratar la enfermedad de alzheimer.
MD2903F1 (en) Medicinal remedy for treatment of central and peripheral nervous system to children
PE20240227A1 (es) Gotas para los ojos para inhibir la progresion de la miopia en ninos y metodos de cribado del inhibidor de la progresion de la miopia en ninos
TH18138C3 (th) สูตรเครื่องดื่มที่มีส่วนผสมของวิตามิน
王致智 This Memorial Day Remembers Our Fallen Heroes
Gloster, Jr et al. Actinic Keratosis